Modern Healthcare writes of an Institute for Clinical and Economic Review (ICER) project that will compare the cost and benefit of costly drugs. ICER will begin releasing reports that will compare clinical effectiveness of drugs, compare prices and their potential impact on the U.S. healthcare system and economy. The agency will then set a value-based benchmark for pricing. The ICER project is funded by a $5.2 million grant from the Laura and John Arnold Foundation, a private foundation that encourages evidence-based and multidisciplinary approaches to address challenges in various sectors, including education, policy and healthcare. The reports will reference how prices are directly linked to the drugs’ ability to improve the health of patients.
Project Announced to Compare Cost, Benefit of Costly Drugs
More from United StatesMore posts in United States »
- New Study Compares Prices and Price Transparency Among Top-Ranked Hospitals and Close Competitors
- New Study: No Surprises Act Prevented Over Two Million Potential Surprise Bills for Insured Americans
- Leapfrog Group Call to Action: Don’t Let CMS Suppress Data on 25,000 Deaths a Year in Hospitals
- HCCI 2020 Health Care Cost and Utilization Report
- Results From International Pilot Survey on Health Care Environmental Hygiene at Facility Level Highlights Need for Improvement